burzynski research institute (BZYR) Snapshot

Burzynski Research Institute’s common stock has been deleted from OTC Bulletin Board (OTCBB) effective July 23, 2012 on account of its ineligibility for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11.

On February 29, 2012, Stanislaw R. Burzynski, M.D., Ph.D., tendered his planned resignation as the Treasurer and the Secretary of Burzynski Research Institute pursuant to a resignation letter received by the company as of such date. Dr. Burzynski will continue to serve as the President of the company and Chairman of the Board of Directors. On March 1, 2012, the company appointed Patryk P. Goscianski, M.B.A., as the Treasurer and the Secretary of the company. On March 1, 2012, the company appointed Tomasz Janicki, M.D., as the Vice President of Clinical Trials of the company.

On September 8, 2011, the board of directors of Burzynski Research Institute unanimously elected Dr. Gregory S. Burzynski to fill a vacancy on the board of directors. Dr. Gregory S. Burzynski is a licensed medical doctor who has worked at the Burzynski Clinic in Houston, Texas since July, 2010. He is currently the vice president of the Burzynski Clinic and is expected to be a valuable member of the board of directors of the company. In addition, Dr. Gregory S. Burzynski is board certified in internal medicine and has been involved in co-authoring numerous publications regarding Antineoplastons.